Xiaodong Wang Sells 2,007 Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Xiaodong Wang sold 2,007 shares of the business's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $265.50, for a total value of $532,858.50. The sale was disclosed in a filing with the SEC, which is available through this link.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, June 10th, Xiaodong Wang sold 41,760 shares of BeOne Medicines stock. The shares were sold at an average price of $262.82, for a total value of $10,975,363.20.
• On Tuesday, May 13th, Xiaodong Wang sold 41,760 shares of BeOne Medicines stock. The shares were sold at an average price of $223.50, for a total value of $9,333,360.00.
• On Monday, April 14th, Xiaodong Wang sold 41,760 shares of BeOne Medicines stock. The shares were sold at an average price of $242.66, for a total value of $10,133,481.60.

BeOne Medicines Price Performance

NASDAQ:ONC traded down $13.29 during trading hours on Friday, reaching $241.20. 400,801 shares of the stock were exchanged, compared to its average volume of 340,778. BeOne Medicines Ltd. - Sponsored ADR has a twelve month low of $141.84 and a twelve month high of $287.88. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. The company's 50 day simple moving average is $247.90. The stock has a market capitalization of $26.44 billion, a PE ratio of -64.84 and a beta of 0.30.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. Equities research analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ONC. Guggenheim upped their price target on BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Morgan Stanley upped their price target on BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research note on Friday. Sanford C. Bernstein set a $259.00 price target on BeOne Medicines in a research note on Thursday, March 13th. TD Securities reaffirmed a "buy" rating and issued a $334.00 price target on shares of BeOne Medicines in a research note on Thursday, April 24th. Finally, Wall Street Zen raised BeOne Medicines from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, BeOne Medicines currently has a consensus rating of "Buy" and an average target price of $320.67.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.